Every 10-Q that IPG Photonics Corporation (IPGP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow IPGP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IPGP filings page.
IPG Photonics reported Q2 2026 net sales of about $278.6M, up 11.1% year over year, with first‑half sales near $544.1M, up 13.7%. Growth was driven by Industrial Solutions, especially welding, cleaning, marking and services, while Advanced Solutions declined. Gross margin improved to 40.4% from 37.3%, helped by lower product costs and $4.7M of tariff refunds that added about 170 basis points, partly offset by higher unabsorbed manufacturing costs.
Despite stronger revenue, net income fell to $5.2M in Q2 and $6.8M for the first half, constrained by a high tax rate and non‑recurring items. The company booked a $17.6M impairment tied to the planned sale of its Belarus operations, now classified as held for sale, and a $13.3M patent litigation settlement with Trumpf. Operating cash flow strengthened to $32.3M in the first half, with $399.2M of cash and $472.1M of short‑term investments and no borrowings under a revolving credit facility. After quarter‑end IPG signed a put option to acquire Lumibird Medical for €300,000 plus up to €50,000 earn‑out, expected to close in the fourth quarter of 2026 subject to French approvals.
IPG Photonics reported higher sales but sharply lower profit for the quarter ended March 31, 2026. Net sales rose 16.6% to $265.5 million, driven mainly by Industrial Solutions, which grew 21.0% and made up 85.7% of revenue. Lasers and Components remained the largest product category at $213.7 million, with Systems up 28.2% to $51.8 million.
Despite the revenue growth, operating results weakened. A $13.5 million charge for settlement of patent litigation with Trumpf and higher tariffs contributed to an operating loss of $7.7 million and reduced net income to $1.6 million, or $0.04 per diluted share, down from $0.09 a year earlier. Gross margin was pressured by higher product costs and about 160 basis points of additional tariff impact.
Cash generation and the balance sheet remain strong. Cash and cash equivalents increased to $480.8 million, total short-term investments were $332.1 million, and the company had no borrowings on its $200 million U.S. revolving credit facility. Management highlighted ongoing geopolitical, tariff and Belarus-related risks but noted no new material operational disruptions.
IPG Photonics (IPGP) reported Q3 2025 results with net sales of $250.8 million, up 7.6% year over year. Gross margin improved to 39.5% from 23.2% as last year included elevated inventory provisions, and cost absorption improved. Operating income was $7.9 million versus a loss a year ago, and diluted EPS was $0.18 compared to a loss of $5.33.
Materials processing remained the core at 87.5% of revenue, with growth in welding, additive, cleaning and micromachining. Medium power CW and QCW lasers rose, while high power CW declined. Foreign exchange was a headwind, and management quantified tariffs as reducing gross margin by about 140 basis points versus last year.
Cash and cash equivalents were $346.0 million and short‑term investments $524.4 million. Year‑to‑date operating cash flow was $46.5 million. The company repurchased 214,408 shares in Q3 (average price $75.99) and 705,390 year‑to‑date; $3.7 million remains under the February 2024 authorization. A new $200 million unsecured revolving credit facility was put in place and was undrawn at quarter‑end.